← All trials
NCT04587141
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2020
- Primary completion
- Jun 30, 2023
- Completion date
- Jun 30, 2023
- First posted
- Oct 14, 2020
- Last posted
- Oct 19, 2020
- Enrollment
- 300
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of PaviaLead sponsor
- University of PaviaReponsible party - principal investigator
- University of PaviaOverall official - principal investigator
- Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.